{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:53:08Z","timestamp":1777870388836,"version":"3.51.4"},"reference-count":85,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T00:00:00Z","timestamp":1576627200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T00:00:00Z","timestamp":1576627200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s40620-019-00679-y","type":"journal-article","created":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T04:04:31Z","timestamp":1576641871000},"page":"223-237","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["ADPKD current management and ongoing trials"],"prefix":"10.1093","volume":"33","author":[{"given":"Francesca","family":"Testa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3319-0248","authenticated-orcid":false,"given":"Riccardo","family":"Magistroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,12,18]]},"reference":[{"key":"679_CR1","first-page":"154","volume":"10","author":"M Pippias","year":"2017","unstructured":"Pippias M, Kramer A, Noordzij M et al (2017) The european renal association \u2013 european dialysis and transplant association registry annual report 2014: a summary. Clin Kidney J 10:154\u2013169","journal-title":"Clin Kidney J"},{"issue":"4","key":"679_CR2","doi-asserted-by":"publisher","first-page":"iv15","DOI":"10.1093\/ndt\/gfu017","volume":"29","author":"EM Spithoven","year":"2014","unstructured":"Spithoven EM, Kramer A, Meijer E et al (2014) Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival\u2013an analysis of data from the ERA-EDTA Registry. Nephrol Dial Transplant 29(4):iv15\u2013iv25","journal-title":"Nephrol Dial Transplant"},{"key":"679_CR3","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.ajhg.2016.05.004","volume":"98","author":"B Porath","year":"2016","unstructured":"Porath B, Gainullin VG, Cornec-Le Gall E et al (2016) Mutations in GANAB, encoding the glucosidase iialpha subunit, cause autosomal-dominant polycystic kidney and liver disease. Am J Hum Genet 98:1193\u20131207","journal-title":"Am J Hum Genet"},{"key":"679_CR4","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.ajhg.2018.03.013","volume":"102","author":"E Cornec-Le Gall","year":"2018","unstructured":"Cornec-Le Gall E, Olson RJ, Besse W et al (2018) Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease. Am J Hum Genet 102:832\u2013844","journal-title":"Am J Hum Genet"},{"key":"679_CR5","doi-asserted-by":"publisher","first-page":"e0190430","DOI":"10.1371\/journal.pone.0190430","volume":"13","author":"A Solazzo","year":"2018","unstructured":"Solazzo A, Testa F, Giovanella S et al (2018) The prevalence of autosomal dominant polycystic kidney disease (ADPKD): a meta-analysis of European literature and prevalence evaluation in the Italian province of Modena suggest that ADPKD is a rare and underdiagnosed condition. PLoS One 13:e0190430","journal-title":"PLoS One"},{"key":"679_CR6","first-page":"860","volume":"287","author":"Y Yamamura","year":"1998","unstructured":"Yamamura Y, Nakamura S, Itoh S et al (1998) OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 287:860\u2013867","journal-title":"J Pharmacol Exp Ther"},{"key":"679_CR7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/(SICI)1520-6408(1999)24:3\/4<309::AID-DVG14>3.0.CO;2-5","volume":"24","author":"VH Gattone 2nd","year":"1999","unstructured":"Gattone VH 2nd, Maser RL, Tian C et al (1999) Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Dev Genet 24:309\u2013318","journal-title":"Dev Genet"},{"key":"679_CR8","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/nm935","volume":"9","author":"VH Gattone 2nd","year":"2003","unstructured":"Gattone VH 2nd, Wang X, Harris PC et al (2003) Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9:1323\u20131326","journal-title":"Nat Med"},{"key":"679_CR9","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nm1004","volume":"10","author":"VE Torres","year":"2004","unstructured":"Torres VE, Wang X, Qian Q et al (2004) Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 10:363\u2013364","journal-title":"Nat Med"},{"key":"679_CR10","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O et al (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367:2407\u20132418","journal-title":"N Engl J Med"},{"key":"679_CR11","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1046\/j.1523-1755.2003.00185.x","volume":"64","author":"AB Chapman","year":"2003","unstructured":"Chapman AB, Guay-Woodford LM, Grantham JJ et al (2003) Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the consortium for radiologic imaging studies of polycystic kidney disease (CRISP) cohort. Kidney Int 64:1035\u20131045","journal-title":"Kidney Int"},{"key":"679_CR12","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2215\/CJN.06300615","volume":"11","author":"VE Torres","year":"2016","unstructured":"Torres VE, Higashihara E, Devuyst O et al (2016) Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 trial. Clin J Am Soc Nephrol 11:803\u2013811","journal-title":"Clin J Am Soc Nephrol"},{"key":"679_CR13","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1053\/j.ajkd.2014.11.010","volume":"65","author":"WE Boertien","year":"2015","unstructured":"Boertien WE, Meijer E, de Jong PE et al (2015) Short-term effects of tolvaptan in individuals with autosomal dominant polycystic kidney disease at various levels of kidney function. Am J Kidney Dis 65:833\u2013841","journal-title":"Am J Kidney Dis"},{"key":"679_CR14","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/ki.2009.325","volume":"76","author":"VE Torres","year":"2009","unstructured":"Torres VE (2009) Vasopressin in chronic kidney disease: an elephant in the room? Kidney Int 76:925\u2013928","journal-title":"Kidney Int"},{"issue":"3","key":"679_CR15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/ndt\/gfx043","volume":"33","author":"VE Torres","year":"2018","unstructured":"Torres VE, Chapman AB, Devuyst O et al (2018) Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant 33(3):477\u2013489. https:\/\/doi.org\/10.1093\/ndt\/gfx043","journal-title":"Nephrol Dial Transplant"},{"key":"679_CR16","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1093\/ndt\/gfv422","volume":"31","author":"RT Gansevoort","year":"2016","unstructured":"Gansevoort RT, Meijer E, Chapman AB et al (2016) Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial. Nephrol Dial Transplant 31:1887\u20131894","journal-title":"Nephrol Dial Transplant"},{"key":"679_CR17","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","volume":"38","author":"PB Watkins","year":"2015","unstructured":"Watkins PB, Lewis JH, Kaplowitz N et al (2015) Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database. Drug Saf 38:1103\u20131113","journal-title":"Drug Saf"},{"key":"679_CR18","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O et al (2017) Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med 377:1930\u20131942","journal-title":"N Engl J Med"},{"key":"679_CR19","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1681\/ASN.2006030251","volume":"17","author":"S Nagao","year":"2006","unstructured":"Nagao S, Nishii K, Katsuyama M et al (2006) Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 17:2220\u20132227","journal-title":"J Am Soc Nephrol"},{"key":"679_CR20","doi-asserted-by":"publisher","first-page":"192","DOI":"10.2215\/CJN.03950510","volume":"6","author":"CJ Wang","year":"2011","unstructured":"Wang CJ, Creed C, Winklhofer FT et al (2011) Water prescription in autosomal dominant polycystic kidney disease: a pilot study. Clin J Am Soc Nephrol 6:192\u2013197","journal-title":"Clin J Am Soc Nephrol"},{"key":"679_CR21","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2215\/CJN.04180609","volume":"5","author":"I Barash","year":"2010","unstructured":"Barash I, Ponda MP, Goldfarb DS et al (2010) A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 5:693\u2013697","journal-title":"Clin J Am Soc Nephrol"},{"key":"679_CR22","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1093\/ndt\/gfu093","volume":"29","author":"E Higashihara","year":"2014","unstructured":"Higashihara E, Nutahara K, Tanbo M et al (2014) Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease? Nephrol Dial Transplant 29:1710\u20131719","journal-title":"Nephrol Dial Transplant"},{"key":"679_CR23","doi-asserted-by":"publisher","first-page":"e003666","DOI":"10.1136\/bmjopen-2013-003666","volume":"3","author":"WF Clark","year":"2013","unstructured":"Clark WF, Sontrop JM, Huang SH et al (2013) The chronic kidney disease water intake trial (WIT): results from the pilot randomised controlled trial. BMJ Open 3:e003666","journal-title":"BMJ Open"},{"key":"679_CR24","doi-asserted-by":"publisher","first-page":"e008634","DOI":"10.1136\/bmjopen-2015-008634","volume":"5","author":"JM Sontrop","year":"2015","unstructured":"Sontrop JM, Huang SH, Garg AX et al (2015) Effect of increased water intake on plasma copeptin in patients with chronic kidney disease: results from a pilot randomised controlled trial. BMJ Open 5:e008634","journal-title":"BMJ Open"},{"key":"679_CR25","first-page":"e022859","volume":"8","author":"R El-Damanawi","year":"2018","unstructured":"El-Damanawi R, Lee M, Harris T et al (2018) Randomised controlled trial of high versus ad libitum water intake in patients with autosomal dominant polycystic kidney disease: rationale and design of the DRINK feasibility trial. BMJ Open 8:e022859","journal-title":"BMJ Open"},{"key":"679_CR26","unstructured":"<e018794.full.pdf>"},{"key":"679_CR27","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","volume":"68","author":"P Ruggenenti","year":"2005","unstructured":"Ruggenenti P, Remuzzi A, Ondei P et al (2005) Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 68:206\u2013216","journal-title":"Kidney Int"},{"key":"679_CR28","first-page":"R329","volume":"249","author":"P Silva","year":"1985","unstructured":"Silva P, Stoff JS, Leone DR et al (1985) Mode of action of somatostatin to inhibit secretion by shark rectal gland. Am J Physiol 249:R329\u2013R334","journal-title":"Am J Physiol"},{"key":"679_CR29","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1681\/ASN.V95903","volume":"9","author":"LP Sullivan","year":"1998","unstructured":"Sullivan LP, Wallace DP, Grantham JJ (1998) Chloride and fluid secretion in polycystic kidney disease. J Am Soc Nephrol 9:903\u2013916","journal-title":"J Am Soc Nephrol"},{"key":"679_CR30","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1369\/jhc.2008.950998","volume":"56","author":"S Bhandari","year":"2008","unstructured":"Bhandari S, Watson N, Long E et al (2008) Expression of somatostatin and somatostatin receptor subtypes 1-5 in human normal and diseased kidney. J Histochem Cytochem 56:733\u2013743","journal-title":"J Histochem Cytochem"},{"issue":"1661\u20131668","key":"679_CR31","doi-asserted-by":"publisher","first-page":"e1661","DOI":"10.1053\/j.gastro.2009.07.052","volume":"137","author":"L van Keimpema","year":"2009","unstructured":"van Keimpema L, Nevens F, Vanslembrouck R et al (2009) Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 137(1661\u20131668):e1661\u2013e1662","journal-title":"Gastroenterology"},{"key":"679_CR32","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","volume":"382","author":"A Caroli","year":"2013","unstructured":"Caroli A, Perico N, Perna A et al (2013) Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet 382:1485\u20131495","journal-title":"Lancet"},{"key":"679_CR33","doi-asserted-by":"publisher","first-page":"e1002777","DOI":"10.1371\/journal.pmed.1002777","volume":"16","author":"N Perico","year":"2019","unstructured":"Perico N, Ruggenenti P, Perna A et al (2019) Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): a randomized, double-blind, placebo-controlled, multicenter trial. PLoS Med 16:e1002777","journal-title":"PLoS Med"},{"key":"679_CR34","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.15870","author":"E Meijer","year":"2018","unstructured":"Meijer E, Visser FW, van Aerts RMM et al (2018) Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial. JAMA. https:\/\/doi.org\/10.1001\/jama.2018.15870","journal-title":"JAMA"},{"key":"679_CR35","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/S0022-2275(20)41159-9","volume":"35","author":"GD Deshmukh","year":"1994","unstructured":"Deshmukh GD, Radin NS, Gattone VH 2nd et al (1994) Abnormalities of glycosphingolipid, sulfatide, and ceramide in the polycystic (cpk\/cpk) mouse. J Lipid Res 35:1611\u20131618","journal-title":"J Lipid Res"},{"key":"679_CR36","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/nm.2171","volume":"16","author":"TA Natoli","year":"2010","unstructured":"Natoli TA, Smith LA, Rogers KA et al (2010) Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat Med 16:788\u2013792","journal-title":"Nat Med"},{"key":"679_CR37","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1093\/hmg\/dds172","volume":"21","author":"TA Natoli","year":"2012","unstructured":"Natoli TA, Husson H, Rogers KA et al (2012) Loss of GM3 synthase gene, but not sphingosine kinase 1, is protective against murine nephronophthisis-related polycystic kidney disease. Hum Mol Genet 21:3397\u20133407","journal-title":"Hum Mol Genet"},{"issue":"1","key":"679_CR38","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2013101138","volume":"26","author":"MV Irazabal","year":"2015","unstructured":"Irazabal MV, Rangel LJ, Bergstralh EJ et al (2015) Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol 26(1):160\u2013172. https:\/\/doi.org\/10.1681\/ASN.2013101138","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"679_CR39","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41581-018-0051-1","volume":"14","author":"V Padovano","year":"2018","unstructured":"Padovano V, Podrini C, Boletta A et al (2018) Metabolism and mitochondria in polycystic kidney disease research and therapy. Nat Rev Nephrol 14(11):678\u2013687. https:\/\/doi.org\/10.1038\/s41581-018-0051-1","journal-title":"Nat Rev Nephrol"},{"key":"679_CR40","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1126\/science.123.3191.309","volume":"123","author":"O Warburg","year":"1956","unstructured":"Warburg O (1956) On the origin of cancer cells. Science 123:309\u2013314","journal-title":"Science"},{"key":"679_CR41","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029\u20131033","journal-title":"Science"},{"issue":"7","key":"679_CR42","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1681\/ASN.2015030231","volume":"27","author":"M Chiaravalli","year":"2016","unstructured":"Chiaravalli M, Rowe I, Mannella V et al (2016) 2-Deoxy-d-Glucose ameliorates PKD progression. J Am Soc Nephrol 27(7):1958\u20131969. https:\/\/doi.org\/10.1681\/ASN.2015030231","journal-title":"J Am Soc Nephrol"},{"key":"679_CR43","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/nm.3092","volume":"19","author":"I Rowe","year":"2013","unstructured":"Rowe I, Chiaravalli M, Mannella V et al (2013) Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat Med 19:488\u2013493","journal-title":"Nat Med"},{"key":"679_CR44","doi-asserted-by":"publisher","first-page":"e0146654","DOI":"10.1371\/journal.pone.0146654","volume":"11","author":"M Riwanto","year":"2016","unstructured":"Riwanto M, Kapoor S, Rodriguez D et al (2016) Inhibition of aerobic glycolysis attenuates disease progression in polycystic kidney disease. PLoS One 11:e0146654","journal-title":"PLoS One"},{"key":"679_CR45","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1096\/fj.201700909R","volume":"32","author":"AS Nikonova","year":"2018","unstructured":"Nikonova AS, Deneka AY, Kiseleva AA et al (2018) Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD). FASEB J 32:2735\u20132746","journal-title":"FASEB J"},{"key":"679_CR46","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.molmed.2011.06.003","volume":"17","author":"O Ibraghimov-Beskrovnaya","year":"2011","unstructured":"Ibraghimov-Beskrovnaya O, Natoli TA (2011) mTOR signaling in polycystic kidney disease. Trends Mol Med 17:625\u2013633","journal-title":"Trends Mol Med"},{"key":"679_CR47","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1073\/pnas.1011498108","volume":"108","author":"V Takiar","year":"2011","unstructured":"Takiar V, Nishio S, Seo-Mayer P et al (2011) Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci USA 108:2462\u20132467","journal-title":"Proc Natl Acad Sci USA"},{"key":"679_CR48","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1172\/JCI64401","volume":"123","author":"X Zhou","year":"2013","unstructured":"Zhou X, Fan LX, Sweeney WE Jr et al (2013) Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease. J Clin Invest 123:3084\u20133098","journal-title":"J Clin Invest"},{"key":"679_CR49","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1681\/ASN.2004080660","volume":"16","author":"Y Tao","year":"2005","unstructured":"Tao Y, Kim J, Schrier RW et al (2005) Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 16:46\u201351","journal-title":"J Am Soc Nephrol"},{"key":"679_CR50","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1056\/NEJMoa0907419","volume":"363","author":"AL Serra","year":"2010","unstructured":"Serra AL, Poster D, Kistler AD et al (2010) Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 363:820\u2013829","journal-title":"N Engl J Med"},{"key":"679_CR51","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1056\/NEJMoa1003491","volume":"363","author":"G Walz","year":"2010","unstructured":"Walz G, Budde K, Mannaa M et al (2010) Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 363:830\u2013840","journal-title":"N Engl J Med"},{"issue":"5","key":"679_CR52","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1681\/ASN.2015020132","volume":"27","author":"G Warner","year":"2016","unstructured":"Warner G, Hein KZ, Nin V et al (2016) Food restriction ameliorates the development of polycystic kidney disease. J Am Soc Nephrol 27(5):1437\u20131447. https:\/\/doi.org\/10.1681\/ASN.2015020132","journal-title":"J Am Soc Nephrol"},{"key":"679_CR53","doi-asserted-by":"publisher","first-page":"F726","DOI":"10.1152\/ajprenal.00551.2015","volume":"310","author":"KR Kipp","year":"2016","unstructured":"Kipp KR, Rezaei M, Lin L et al (2016) A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease. Am J Physiol Renal Physiol 310:F726\u2013F731","journal-title":"Am J Physiol Renal Physiol"},{"key":"679_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1681\/ASN.2016070785","volume":"28","author":"A Jacob","year":"2017","unstructured":"Jacob A, Torres CMB, Kruger Samantha, Schimmel Margaret F, Weimbs Thomas (2017) A ketogenic diet slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 28:1","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"679_CR55","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1093\/ndt\/gfi181","volume":"21","author":"PR Wahl","year":"2006","unstructured":"Wahl PR, Serra AL, Le Hir M et al (2006) Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 21(3):598\u2013604. https:\/\/doi.org\/10.1093\/ndt\/gfi181","journal-title":"Nephrol Dial Transplant"},{"key":"679_CR56","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1111\/j.1600-6143.2010.03152.x","volume":"10","author":"G Canaud","year":"2010","unstructured":"Canaud G, Knebelmann B, Harris PC et al (2010) Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: what is the appropriate serum level? Am J Transplant 10:1701\u20131706","journal-title":"Am J Transplant"},{"key":"679_CR57","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1056\/NEJMoa054341","volume":"354","author":"JJ Grantham","year":"2006","unstructured":"Grantham JJ, Torres VE, Chapman AB et al (2006) Volume progression in polycystic kidney disease. N Engl J Med 354:2122\u20132130","journal-title":"N Engl J Med"},{"key":"679_CR58","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1681\/ASN.2009121291","volume":"21","author":"MC Hogan","year":"2010","unstructured":"Hogan MC, Masyuk TV, Page LJ et al (2010) Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 21:1052\u20131061","journal-title":"J Am Soc Nephrol"},{"key":"679_CR59","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.124.3215.269","volume":"124","author":"O Warburg","year":"1956","unstructured":"Warburg O (1956) On respiratory impairment in cancer cells. Science 124:269\u2013270","journal-title":"Science"},{"key":"679_CR60","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrc2817","volume":"10","author":"DA Tennant","year":"2010","unstructured":"Tennant DA, Duran RV, Gottlieb E (2010) Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 10:267\u2013277","journal-title":"Nat Rev Cancer"},{"key":"679_CR61","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nm.3140","volume":"19","author":"C Priolo","year":"2013","unstructured":"Priolo C, Henske EP (2013) Metabolic reprogramming in polycystic kidney disease. Nat Med 19:407\u2013409","journal-title":"Nat Med"},{"key":"679_CR62","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0360-3016(96)85017-6","volume":"35","author":"BK Mohanti","year":"1996","unstructured":"Mohanti BK, Rath GK, Anantha N et al (1996) Improving cancer radiotherapy with 2-deoxy-d-glucose: phase I\/II clinical trials on human cerebral gliomas. Int J Radiat Oncol Biol Phys 35:103\u2013111","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"679_CR63","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00280-012-2045-1","volume":"71","author":"LE Raez","year":"2013","unstructured":"Raez LE, Papadopoulos K, Ricart AD et al (2013) A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 71:523\u2013530","journal-title":"Cancer Chemother Pharmacol"},{"key":"679_CR64","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00066-005-1320-z","volume":"181","author":"D Singh","year":"2005","unstructured":"Singh D, Banerji AK, Dwarakanath BS et al (2005) Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol 181:507\u2013514","journal-title":"Strahlenther Onkol"},{"key":"679_CR65","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1002\/pros.21172","volume":"70","author":"M Stein","year":"2010","unstructured":"Stein M, Lin H, Jeyamohan C et al (2010) Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate 70:1388\u20131394","journal-title":"Prostate"},{"key":"679_CR66","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4103\/1793-5482.110274","volume":"8","author":"NK Venkataramanaa","year":"2013","unstructured":"Venkataramanaa NK, Venkatesh PK, Dwarakanath BS et al (2013) Protective effect on normal brain tissue during a combinational therapy of 2-deoxy-d-glucose and hypofractionated irradiation in malignant gliomas. Asian J Neurosurg 8:9\u201314","journal-title":"Asian J Neurosurg"},{"key":"679_CR67","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s40620-017-0395-9","volume":"30","author":"R Magistroni","year":"2017","unstructured":"Magistroni R, Boletta A (2017) Defective glycolysis and the use of 2-deoxy-d-glucose in polycystic kidney disease: from animal models to humans. J Nephrol 30:511\u2013519","journal-title":"J Nephrol"},{"key":"679_CR68","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ebiom.2016.01.027","volume":"5","author":"LF Menezes","year":"2016","unstructured":"Menezes LF, Lin CC, Zhou F et al (2016) Fatty Acid oxidation is impaired in an orthologous mouse model of autosomal dominant polycystic kidney disease. EBioMedicine 5:183\u2013192","journal-title":"EBioMedicine"},{"key":"679_CR69","doi-asserted-by":"publisher","first-page":"F122","DOI":"10.1152\/ajprenal.00352.2017","volume":"314","author":"R Lakhia","year":"2018","unstructured":"Lakhia R, Yheskel M, Flaten A et al (2018) PPARalpha agonist fenofibrate enhances fatty acid beta-oxidation and attenuates polycystic kidney and liver disease in mice. Am J Physiol Renal Physiol 314:F122\u2013F131","journal-title":"Am J Physiol Renal Physiol"},{"key":"679_CR70","first-page":"274376","volume":"2010","author":"BL Blazer-Yost","year":"2010","unstructured":"Blazer-Yost BL, Haydon J, Eggleston-Gulyas T et al (2010) Pioglitazone attenuates cystic burden in the PCK rodent model of polycystic kidney disease. PPAR Res 2010:274376","journal-title":"PPAR Res"},{"key":"679_CR71","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1042\/CS20100113","volume":"119","author":"B Dai","year":"2010","unstructured":"Dai B, Liu Y, Mei C et al (2010) Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats. Clin Sci (Lond) 119:323\u2013333","journal-title":"Clin Sci (Lond)"},{"key":"679_CR72","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1515\/jtim-2016-0028","volume":"4","author":"SM Flaig","year":"2016","unstructured":"Flaig SM, Gattone VH, Blazer-Yost BL (2016) Inhibition of cyst growth in PCK and Wpk rat models of polycystic kidney disease with low doses of peroxisome proliferator-activated receptor gamma agonists. J Transl Int Med 4:118\u2013126","journal-title":"J Transl Int Med"},{"key":"679_CR73","doi-asserted-by":"publisher","first-page":"F465","DOI":"10.1152\/ajprenal.00460.2010","volume":"300","author":"D Yoshihara","year":"2011","unstructured":"Yoshihara D, Kurahashi H, Morita M et al (2011) PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. Am J Physiol Renal Physiol 300:F465\u2013F474","journal-title":"Am J Physiol Renal Physiol"},{"key":"679_CR74","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40620-018-0470-x","volume":"31","author":"BR Di Iorio","year":"2018","unstructured":"Di Iorio BR, Cupisti A, D\u2019Alessandro C et al (2018) Nutritional therapy in autosomal dominant polycystic kidney disease. J Nephrol 31:635\u2013643","journal-title":"J Nephrol"},{"key":"679_CR75","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40620-017-0396-8","volume":"31","author":"L Girardat-Rotar","year":"2018","unstructured":"Girardat-Rotar L, Puhan MA, Braun J et al (2018) Long-term effect of coffee consumption on autosomal dominant polycystic kidneys disease progression: results from the Suisse ADPKD, a prospective longitudinal cohort study. J Nephrol 31:87\u201394","journal-title":"J Nephrol"},{"key":"679_CR76","doi-asserted-by":"publisher","first-page":"100154","DOI":"10.1016\/j.phanu","volume":"9","author":"F Testa","year":"2019","unstructured":"Testa F, Marchi\u00f2 M, Belli M et al (2019) A pilot study to evaluate Tolerability and Safety of a Modified Atkins Diet in ADPKD patients. PharmaNutrition 9:100154. https:\/\/doi.org\/10.1016\/j.phanu","journal-title":"PharmaNutrition"},{"key":"679_CR77","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1046\/j.1523-1755.2003.00232.x","volume":"64","author":"WE Sweeney Jr","year":"2003","unstructured":"Sweeney WE Jr, Hamahira K, Sweeney J et al (2003) Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability. Kidney Int 64:1310\u20131319","journal-title":"Kidney Int"},{"key":"679_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9050052","author":"P Wee","year":"2017","unstructured":"Wee P, Wang Z (2017) Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers9050052","journal-title":"Cancers (Basel)"},{"key":"679_CR79","doi-asserted-by":"publisher","first-page":"188","DOI":"10.5527\/wjn.v6.i4.188","volume":"6","author":"WE Sweeney","year":"2017","unstructured":"Sweeney WE, Frost P, Avner ED (2017) Tesevatinib ameliorates progression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease. World J Nephrol 6:188\u2013200","journal-title":"World J Nephrol"},{"key":"679_CR80","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1046\/j.1523-1755.2000.00829.x","volume":"57","author":"WE Sweeney","year":"2000","unstructured":"Sweeney WE, Chen Y, Nakanishi K et al (2000) Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int 57:33\u201340","journal-title":"Kidney Int"},{"issue":"11","key":"679_CR81","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1681\/ASN.2016111232","volume":"28","author":"V Tesar","year":"2017","unstructured":"Tesar V, Ciechanowski K, Pei Y et al (2017) Bosutinib versus placebo for autosomal dominant polycystic kidney disease. J Am Soc Nephrol 28(11):3404\u20133413. https:\/\/doi.org\/10.1681\/ASN.2016111232","journal-title":"J Am Soc Nephrol"},{"key":"679_CR82","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1681\/ASN.2007060665","volume":"19","author":"WE Sweeney Jr","year":"2008","unstructured":"Sweeney WE Jr, von Vigier RO, Frost P et al (2008) Src inhibition ameliorates polycystic kidney disease. J Am Soc Nephrol 19:1331\u20131341","journal-title":"J Am Soc Nephrol"},{"key":"679_CR83","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/nrd.2016.184","volume":"15","author":"RK Harrison","year":"2016","unstructured":"Harrison RK (2016) Phase II and phase III failures: 2013\u20132015. Nat Rev Drug Discov 15:817\u2013818","journal-title":"Nat Rev Drug Discov"},{"key":"679_CR84","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40620-016-0358-6","volume":"30","author":"IA Iliuta","year":"2017","unstructured":"Iliuta IA, Kitchlu A, Pei Y (2017) Methodological issues in clinical trials of polycystic kidney disease: a focused review. J Nephrol 30:363\u2013371","journal-title":"J Nephrol"},{"key":"679_CR85","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1056\/NEJMe1006925","volume":"363","author":"T Watnick","year":"2010","unstructured":"Watnick T, Germino GG (2010) mTOR inhibitors in polycystic kidney disease. N Engl J Med 363:879\u2013881","journal-title":"N Engl J Med"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-019-00679-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40620-019-00679-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-019-00679-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:56:23Z","timestamp":1777564583000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/33\/2\/223\/8328430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,18]]},"references-count":85,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["679"],"URL":"https:\/\/doi.org\/10.1007\/s40620-019-00679-y","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,18]]},"assertion":[{"value":"3 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"R.M. was involved in the trials of Tolvaptan sponsored by Otsuka Pharmaceutical as Principal Investigator. R.M. is scientific advisor of Otsuka Italia. F.T. does not declare any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This paper did not involve Human Participants and\/or Animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}